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Before clinicians can administer a vaccine in the United States, the FDA must approve and 
license it. Investigators conduct extensive research leading up to this process, typically testing a 
vaccine in thousands of patients over 6 to 7 years or longer.1 Even with large sample sizes and 
rigorous study designs, rare adverse effects may be missed. For example, RotaShield, the first 
vaccine for rotavirus, was withdrawn from the market in 1999, despite being tested in more than 
10,000 patients. Postmarketing surveillance demonstrated that a rare, yet serious, risk of 
intussusception was linked to the vaccine, and the FDA determined that the vaccine’s risks 
outweighed its benefits.2 
 
Once the FDA approves a vaccine, the CDC’s Advisory Committee on Immunization Practices 
(ACIP) can make a recommendation for its use. Although the FDA focuses on the safety and 
efficacy of the vaccine, the ACIP can consider more aspects, such as the epidemiology of the 
disease, health economic impact, and implementation challenges, when making its 
recommendation.3 In addition, the US Department of Defense advocates for expedited 
development, review, and emergency use authorization of medical products that may benefit the 
US military forces or the general public.4 
 
According to the World Health Organization, 240 vaccines were in development for 25 
infectious diseases.5 Topping the list for most candidate vaccines are HIV/AIDS, malaria, 
pneumococcal infections, tuberculosis, and Ebola. 
 





New Delivery Systems 
Combination vaccines are advantageous because they mitigate the burden of multiple injections, 
reduce the number of visits, and save on costs for storage and shipment.20 In 2018, the FDA 
approved a new hexavalent vaccine, DTaP5-HB-IPV- Hib (Vaxelis, Merck) for primary and 
booster vaccination in infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, 
poliomyelitis, and invasive disease caused by Haemophilus influenzae type b.21,22 
 
Vaccine adjuvants are important for eliciting desired protective and sustained immune responses 
against target pathogens.23 In recent years, investigators have studied many novel adjuvants for 
clinical development, such as the oil-in-water emulsion MF59, which is currently being used in 




Vaccine technology has also been applied to the treatment of noninfectious disease conditions 
and areas such as cancer,24 smoking cessation,25 and hypertension.26 Vaccines that target tumor-
associated antigens have been shown to prolong the survival of patients with metastatic 




The challenges that investigators face while developing a vaccine are unique, from infectious 
diseases that mutate at varying rates to efforts to develop a safe vaccine that not only targets the 
correct strain but also elicits an adequate immunologic response. Although this article has 
discussed a handful of vaccines in the pipeline, investigators are evaluating many others on a 
global scale. Despite the obstacles for vaccine development, FDA vaccine approvals have 
accelerated over the past 2 decades, making the prevention of even more human diseases in the 
future a realizable prospect (figure).28 
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